AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34315515 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (early-PN)
Number of subjects: 403
Study 34315515 — intervention group
Group type: COMPARATOR
Intervention: Late parenteral nutrition (late-PN)
Number of subjects: 403
Study 32100494 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic moxibustion at Lianquan (CV 23), Tiantu (CV 22), Tianding (LI 17), and Futu (LI 18), 30 min each treatment, 5 times a week for 4 weeks.
Number of subjects: 60
Study 32100494 — intervention group
Group type: COMPARATOR
Intervention: Routine medical treatment, acupuncture treatment, and swallowing rehabilitation training.
Number of subjects: 60
Study 32100494 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of changes in activity of parapharyngeal wall and dysphagia score between groups.
Number of subjects: 60
Study 35727461 — intervention group
Group type: EXPERIMENTAL
Intervention: New robotic system with wristed microinstruments
Number of subjects: 0
Study 35727461 — intervention group
Group type: COMPARATOR
Intervention: Manual technique
Number of subjects: 0
Study 33480227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of 100 dB noise exposure
Number of subjects: 27
Study 33480227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of 110 dB noise exposure
Number of subjects: 27
Study 33480227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no noise exposure)
Number of subjects: 27
Study 35261120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mcg every 6 h up to 48 h)
Number of subjects: 106
Study 35261120 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (starting with 50 units up to a maximum of 300 units)
Number of subjects: 106
Study 35261120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (second-line treatment)
Number of subjects: 106
Study 35261120 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (second-line treatment)
Number of subjects: 106
Study 35261120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 106
Study 35261120 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 106
Study 32429758 — intervention group
Group type: EXPERIMENTAL
Intervention: SITAR growth curve model applied to pubertal growth data
Number of subjects: 11029
Study 32429758 — intervention group
Group type: EXPERIMENTAL
Intervention: SITAR models fitted to ALSPAC subjects split into 9 by 5 APV and PV groups
Number of subjects: 11029
Study 35511876 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese cohort
Number of subjects: 230
Study 32098758 — intervention group
Group type: COMPARATOR
Intervention: 30 µg sprifermin every 6 months (q6mo)
Number of subjects: 0
Study 32098758 — intervention group
Group type: COMPARATOR
Intervention: 100 µg sprifermin every 6 months (q6mo)
Number of subjects: 0
Study 32098758 — intervention group
Group type: COMPARATOR
Intervention: 100 µg sprifermin every 12 months (q12mo)
Number of subjects: 0
Study 32098758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34481898 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary infrapopliteal vein bypass surgery (BS)
Number of subjects: 60
Study 34481898 — intervention group
Group type: EXPERIMENTAL
Intervention: Best endovascular treatment (BET)
Number of subjects: 60
Study 34481898 — intervention group
Group type: EXPERIMENTAL
Intervention: Major limb major amputation (MLLA)
Number of subjects: 60
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NLR > 5
Number of subjects: 212
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR ≤ 5 on days 1 and 15
Number of subjects: 212
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR > 5 on day 1 and NLR ≤ 5 on day 15
Number of subjects: 212
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR > 5 on days 1 and 15
Number of subjects: 212
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bad responders (PFS < 6 months)
Number of subjects: 212
Study 33055007 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in NLR early during chemotherapy
Number of subjects: 212
Study 34794654 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent-polymer zotarolimus-eluting stent (PP-ZES)
Number of subjects: 1491
Study 34794654 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free Amphilimus-eluting stent (PF-AES)
Number of subjects: 1491
Study 34794654 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PF-AES to PP-ZES
Number of subjects: 1491
Study 36191269 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction-assisted ESD (T-ESD)
Number of subjects: 97
Study 36191269 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD (C-ESD)
Number of subjects: 97
Study 33847362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline 1.5 mg
Number of subjects: 254
Study 33847362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline 3 mg
Number of subjects: 254
Study 33847362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline 1.5 mg TID
Number of subjects: 254
Study 33847362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline 3 mg TID
Number of subjects: 254
Study 33847362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 33345674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantente REAL intervention
Number of subjects: 1418
Study 33345674 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 1418
Study 33263732 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 33263732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32410722 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted outdoor residual spraying (TORS)
Number of subjects: 12
Study 32410722 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodissemination devices (ADD)
Number of subjects: 12
Study 32410722 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted outdoor residual spraying + Autodissemination devices (TORS + ADD)
Number of subjects: 12
Study 32410722 — intervention group
Group type: COMPARATOR
Intervention: Control site
Number of subjects: 12
Study 36465382 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-open single-flap technique
Number of subjects: 250
Study 36465382 — intervention group
Group type: COMPARATOR
Intervention: Double-flap technique
Number of subjects: 250
Study 32615114 — intervention group
Group type: EXPERIMENTAL
Intervention: Open radical hysterectomy
Number of subjects: 0
Study 32615114 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 0
Study 36227845 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 50
Study 36227845 — intervention group
Group type: COMPARATOR
Intervention: FICB
Number of subjects: 50
Study 33707996 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Training (EBT)
Number of subjects: 168
Study 33707996 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 168
Study 33896806 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise
Number of subjects: 80
Study 33896806 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 80
Study 34785153 — intervention group
Group type: EXPERIMENTAL
Intervention: OK lenses
Number of subjects: 60
Study 34785153 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacles (control group)
Number of subjects: 60
Study 33388943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed or obligatory dislocators
Number of subjects: 100
Study 33388943 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard traumatic instability patients
Number of subjects: 100
Study 33388943 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 100
Study 32717112 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Number of subjects: 288
Study 32717112 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping
Number of subjects: 288
Study 35057084 — intervention group
Group type: COMPARATOR
Intervention: Placebo—oral (Group A)
Number of subjects: 200
Study 35057084 — intervention group
Group type: COMPARATOR
Intervention: Placebo—sublingual (Group B)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral standard aspirin—100 mg daily (Group C)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral standard aspirin—50 mg daily (Group D)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sublingual aspirin—100 mg (Group E)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sublingual aspirin—50 mg (Group F)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of micronized collagen-cogrinded aspirin (Groups G and H)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual collagen-cogrinded aspirin—100 mg (Group I)
Number of subjects: 200
Study 35057084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual collagen-cogrinded aspirin—50 mg (Group L)
Number of subjects: 200
Study 35099206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and cognitive-behavioral strategies (EC)
Number of subjects: 152
Study 35099206 — intervention group
Group type: COMPARATOR
Intervention: Pain education (control)
Number of subjects: 152
Study 33225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Oral-B Kids)
Number of subjects: 41
Study 33225464 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 41
Study 35938597 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted darunavir with dolutegravir
Number of subjects: 0
Study 35938597 — intervention group
Group type: COMPARATOR
Intervention: Boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
Number of subjects: 0
Study 35938597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD)
Number of subjects: 0
Study 33555671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training
Number of subjects: 27
Study 33555671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 32001336 — intervention group
Group type: EXPERIMENTAL
Intervention: Real transcranial magnetic stimulation (TMS) targeting the superior temporal gyrus (STG) during pain encoding.
Number of subjects: 42
Study 32001336 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation (TMS) during pain encoding.
Number of subjects: 42
Study 35732751 — intervention group
Group type: EXPERIMENTAL
Intervention: ZoneX #2 (5.8 mg nicotine/pouch)
Number of subjects: 24
Study 35732751 — intervention group
Group type: EXPERIMENTAL
Intervention: ZoneX #3 (10.1 mg nicotine/pouch)
Number of subjects: 24
Study 35732751 — intervention group
Group type: COMPARATOR
Intervention: Cigarette
Number of subjects: 24
Study 33771837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab 300 mg
Number of subjects: 230
Study 33771837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 32371660 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus access to a web-based SUD intervention (CBT4CBT)
Number of subjects: 58
Study 32371660 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study 35460388 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral iron therapy (2*80 mg iron sulfate)
Number of subjects: 83
Study 35460388 — intervention group
Group type: COMPARATOR
Intervention: Every other day oral iron therapy (2*80 mg iron sulfate)
Number of subjects: 83
Study 32378183 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest serum selenium quartile
Number of subjects: 1066
Study 33510523 — intervention group
Group type: EXPERIMENTAL
Intervention: Group FP (propofol, midazolam and fentanyl)
Number of subjects: 100
Study 33510523 — intervention group
Group type: COMPARATOR
Intervention: Group P (propofol and midazolam)
Number of subjects: 100
Study 32301116 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse propensity score reweighting methodology
Number of subjects: 0
Study 32301116 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifying treatment effect modifiers
Number of subjects: 0
Study 32301116 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding and managing differences between patient characteristic data sets
Number of subjects: 0
Study 32301116 — intervention group
Group type: EXPERIMENTAL
Intervention: Balancing the closeness of trial and target patient populations with effective sample size
Number of subjects: 0
Study 33622517 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced HNC (TE-HNC)
Number of subjects: 0
Study 33622517 — intervention group
Group type: COMPARATOR
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 0
Study 36082214 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole food diet
Number of subjects: 16
Study 36082214 — intervention group
Group type: COMPARATOR
Intervention: Extruded dry diet
Number of subjects: 16
Study 32763218 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid ART intervention with a dolutegravir-based regimen offered at first clinic visit.
Number of subjects: 1717
Study 32763218 — intervention group
Group type: COMPARATOR
Intervention: Standard ART period before rapid ART introduction.
Number of subjects: 1717
Study 35707193 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial domain attention mechanism in facial expression recognition
Number of subjects: 0
Study 35707193 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid domain attention mechanism combining spatial and channel domain attention
Number of subjects: 0
Study 35707193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule games for developing sustained and selective attention
Number of subjects: 0
Study 35707193 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33617383 — intervention group
Group type: EXPERIMENTAL
Intervention: State laws related to structural racism identified through systematic policy surveillance methods.
Number of subjects: 843
Study 33617383 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive database of structural racism-related state laws developed from 2010 to 2013.
Number of subjects: 843
Study 36163349 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD20 antibodies
Number of subjects: 3830
Study 36163349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3830
Study 36163349 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod
Number of subjects: 3830
Study 34311108 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-Carboplatin-Paclitaxel (ACP)
Number of subjects: 1202
Study 34311108 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel (ABCP)
Number of subjects: 1202
Study 34311108 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-Carboplatin-Paclitaxel (BCP)
Number of subjects: 1202
Study 34661821 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus NSAIs (150 mg)
Number of subjects: 53
Study 34661821 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus NSAIs (150 mg)
Number of subjects: 53
Study 34661821 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 53
Study 34661821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 32092505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin (dual pathway inhibition regimen)
Number of subjects: 10000
Study 32092505 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 10000
Study 33456031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal ceramic (MC) crowns with prefabricated metal posts and composite cores
Number of subjects: 60
Study 33456031 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolithic zirconia (MZ) crowns with glass-fiber posts and composite cores
Number of subjects: 60
Study 33456031 — intervention group
Group type: COMPARATOR
Intervention: Control group with resin filling
Number of subjects: 60
Study 34844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g/kg body weight/day for 14 days)
Number of subjects: 30
Study 34844156 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 30
Study 34844156 — intervention group
Group type: COMPARATOR
Intervention: Control (25 g of sugar in 250 mL of water)
Number of subjects: 30
Study 32696575 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations (PEs) for resting energy expenditure (REE)
Number of subjects: 38
Study 32696575 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting energy expenditure (REE) measured by indirect calorimetry (REE-IC) in MD patients
Number of subjects: 38
Study 32696575 — intervention group
Group type: COMPARATOR
Intervention: Resting energy expenditure (REE) measured by indirect calorimetry (REE-IC) in healthy controls
Number of subjects: 38
Study 32696575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients’ self-estimated physical activity level (PAL)
Number of subjects: 38
Study 32696575 — intervention group
Group type: COMPARATOR
Intervention: Fixed average physical activity level (PAL) of 1.4
Number of subjects: 38
Study 32696575 — intervention group
Group type: COMPARATOR
Intervention: Usual care for estimating total energy expenditure (TEE)
Number of subjects: 38
Study 32696575 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations (PEs) for REE in MD patients
Number of subjects: 38
Study 32696575 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of PAL using accelerometry
Number of subjects: 38
Study 33092558 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash incentive for education (education treatment arm)
Number of subjects: 4819
Study 33092558 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional raffle for testing negative for curable STIs (in both education treatment and control arms)
Number of subjects: 4819
Study 33092558 — intervention group
Group type: COMPARATOR
Intervention: Control arm (education control arm)
Number of subjects: 4819
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg intravenous every 4 weeks (for those who were initially on placebo)
Number of subjects: 268
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg intravenous every 4 weeks (for those who were initially on belimumab)
Number of subjects: 268
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline naïve B cell counts
Number of subjects: 268
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SLE subset plasma and short-lived plasma B cell counts
Number of subjects: 268
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IgG levels
Number of subjects: 268
Study 35131846 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decreases in IgG levels
Number of subjects: 268
Study 34117824 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pilates exercises with childbirth training (Group 1, n = 21)
Number of subjects: 64
Study 34117824 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth training only (Group 2, n = 21)
Number of subjects: 64
Study 34117824 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3, n = 22)
Number of subjects: 64
Study 35305955 — intervention group
Group type: EXPERIMENTAL
Intervention: LABR‐312 infusion (0.01 mg, 0.03 mg, and 0.08 mg)
Number of subjects: 271
Study 35305955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 33250068 — intervention group
Group type: EXPERIMENTAL
Intervention: CORKA home-based rehabilitation programme (median of 5 sessions)
Number of subjects: 621
Study 33250068 — intervention group
Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy (median of 4 sessions)
Number of subjects: 621
Study 33250068 — intervention group
Group type: EXPERIMENTAL
Intervention: CORKA home-based rehabilitation programme
Number of subjects: 621
Study 33250068 — intervention group
Group type: COMPARATOR
Intervention: Usual care outpatient physiotherapy
Number of subjects: 621
Study 35700588 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulating (IM) supplements
Number of subjects: 299
Study 35700588 — intervention group
Group type: COMPARATOR
Intervention: High-protein (HP) supplements
Number of subjects: 299
Study 34554208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (500 mg, once daily)
Number of subjects: 187
Study 34554208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 34554208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 187
Study 34554208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib and Placebo
Number of subjects: 187
Study 32350174 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRC (sweet potato rice cake)
Number of subjects: 0
Study 32350174 — intervention group
Group type: COMPARATOR
Intervention: CHO gel (commercially available jelly drink)
Number of subjects: 0
Study 32350174 — intervention group
Group type: EXPERIMENTAL
Intervention: SPRC
Number of subjects: 0
Study 35782092 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES assisted strength training (n = 30)
Number of subjects: 60
Study 35782092 — intervention group
Group type: COMPARATOR
Intervention: Sham NMES assisted strength training (n = 30)
Number of subjects: 60
Study 35782092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NMES and sham NMES)
Number of subjects: 60
Study 34167653 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mA tDCS
Number of subjects: 33
Study 34167653 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mA tDCS
Number of subjects: 33
Study 34167653 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 33
Study 33030273 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (350 mg/day)
Number of subjects: 49
Study 33030273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49